Načítá se...
Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial
Background and aim: After failure of oxaliplatin, irinotecan, and 5-fluorouracil (5-FU), there is no effective and low-cost therapy for metastatic colorectal cancer (mCRC). The purpose of this study was to assess the efficacy and safety of gemcitabine plus S-1 (GS) versus cetuximab as a third-line c...
Uloženo v:
| Vydáno v: | Int J Clin Exp Med |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
e-Century Publishing Corporation
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4723894/ https://ncbi.nlm.nih.gov/pubmed/26885049 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|